If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Rituximab in cutaneous B-cell lymphoma: a report of two cases

$48.00 plus tax (Refund Policy)

Download / Buy Article:


We report two patients with primary cutaneous B-cell lymphoma who were treated with rituximab, a new anti-CD20 monoclonal antibody. The first patient, who had a diffuse large B-cell lymphoma of the lower leg, achieved an 85% improvement. The second patient, who had a primary cutaneous B-cell lymphoma, which had undergone high-grade transformation and systemic spread, achieved a minor response of approximately 30%. Both patients subsequently relapsed. The first patient achieved complete clearance with a second course of rituximab given with systemic chemotherapy, but again relapsed. Treatment with rituximab has been reported to produce response rates of 48% in relapsed systemic low-grade or follicular lymphoma, but there are no previous reports of the use of rituximab in primary cutaneous B-cell lymphoma.

Keywords: anti-CD20 monoclonal antibody therapy; cutaneous B-cell lymphoma; rituximab

Document Type: Research Article

DOI: http://dx.doi.org/10.1046/j.1365-2133.2000.03607.x

Affiliations: Skin Tumour Unit, St John’s Institute of Dermatology, St Thomas’ Hospital (GKT), London SE1 7EH, U.K.

Publication date: July 1, 2000

Related content



Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more